3′UTR-directed, kinase-proximal mRNA decay inhibits C/EBPβ phosphorylation/activation to suppress senescence in tumor cells

Read full text
Authors: Jacqueline Salotti, Nida Asif, Srikanta Basu, Aniruddha Das, Linshan Hu, Mei Yang, Baktiar Karim, Karen L. Saylor, Nancy Martin, David A. Scheiblin, Sweta Misra, Brian T. Luke
+6 more Þorkell Andrésson, Ming Yi, Mélissa Galloux, Stephen Lockett, Lino Tessarollo, Peter F. Johnson
Cited by: 0
References: 48

Abstract

Abstract C/EBPβ is a potent regulator of oncogene-induced senescence (OIS) and the SASP. C/EBPβ is post-translationally activated in OIS cells by the effector kinases ERK1/2 and CK2. However, in tumor cells C/EBPβ activation is suppressed by its 3’UTR. 3′UTR regulation of protein activity (UPA) requires a G/U-rich element (GRE) and its cognate binding protein, HuR. These components segregate CEBPB transcripts away from a perinuclear compartment harboring ERK1/2 and CK2, restricting C/EBPβ from its activating kinases. We report here that the mRNA decay proteins UPF1 and Staufen1/2 are essential UPA factors enriched within the perinuclear cytoplasm. STAU1/2 and UPF1 overlap with CK2 on perinuclear signaling endosomes where they promote localized CEBPB mRNA decay. UPF1 or STAU1/2 depletion in tumor cells increased CEBPB transcripts adjacent to CK2 foci, coinciding with C/EBPβ activation and senescence. The GRE and an adjacent STAU binding site independently suppress C/EBPβ-mediated senescence, while a distinct 3’UTR region inhibits its SASP-inducing activity. Kras G12D -driven lung tumors in mice carrying a Cebpb GRE deletion rarely progressed to malignant adenocarcinomas, demonstrating the importance of UPA to enable tumor progression in vivo . Thus, kinase-proximal mRNA decay is a novel mechanism that inhibits C/EBPβ activation in tumor cells to facilitate senescence bypass.

Fields of Study & Subjects

RNA Research and Splicing RNA and protein synthesis mechanisms Genomics and Chromatin Dynamics

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
8
Pages
117039–117039
Publication date
1 August 2026
Language
EN